A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer

Introduction: We aimed to investigate several clinical and biochemical parameters, including palliative external beam radiation therapy (EBRT) to predict survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Methods: We tested known and possible prognostic parameters, including palliative EBRT, both prior and concurrent to 223Ra. Log-rank test (Kaplan-Meier method) and Cox regression analysis were used to predict overall survival (OS). Results: A total of 133 patients were treated with 223Ra; median age was 72 years. Median OS was 9.0 (95% confidence interval [CI] 7.4–10.6) months. By univariate analysis (log-rank test), baseline Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 (p=0.001), ≥5 cycles of 223Ra (p